Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29384
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSILVA, Veronica Torres Costa e-
dc.contributor.authorCAIRES, Renato Antunes-
dc.contributor.authorBEZERRA, Juliana Silva-
dc.contributor.authorCOSTALONGA, Elerson C.-
dc.contributor.authorOLIVEIRA, Ana Paula Leandro-
dc.contributor.authorCOELHO, Fernanda Oliveira-
dc.contributor.authorFUKUSHIMA, Julia T.-
dc.contributor.authorSOARES, Cilene Muniz-
dc.contributor.authorOIKAWA, Luciane-
dc.contributor.authorHAJJAR, Ludhmila Abrahao-
dc.contributor.authorBURDMANN, Emmanuel A.-
dc.date.accessioned2018-11-21T17:00:33Z-
dc.date.available2018-11-21T17:00:33Z-
dc.date.issued2018-
dc.identifier.citationJOURNAL OF CRITICAL CARE, v.47, p.302-309, 2018-
dc.identifier.issn0883-9441-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29384-
dc.description.abstractPurpose: This study aimed to evaluate the safety and efficacy of a regional citrate anticoagulation (RCA) protocol for continuous venovenous hemodialysis (CVVHD) in cancer patients with acute kidney injury (AKI) in the intensive care unit (ICU) setting. Material and methods: One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study. Results: A total of 7198 h of CVVHD therapy (250 filters) were performed. Patients were 613 +/- 15.7 years old, 78% had solid cancer and the main AKI cause was sepsis (50%). The in-hospital mortality was 78.7%. Systemic ionized calcium (SCai) was 435 (4.10-4.60) mg/dL, severe hypocalcemia (SCai <3.6 mg/dL) was observed in 4.3% of procedures and post-filter ionized calcium was 1.60 (1.40-1.80) mg/dL. Median filter pa tency was 24.8 (11-43) hours. Factors related to filter clotting were: no tumor evidence (OR 0.44, C10.18-0.99); genitourinary tumor (OR 1.83, CI 1.18-2.81); platelets number (each 10,000/mm(3)) (OR 1.02, CI 1.00-1.04); International Normatized Ratio (INR) (OR 059, CI 0.41-0.85) and citrate dose (each 10 mL/h) (OR 0.88, CI 0.82-0.95). Conclusion: Filler plenty was relatively short and dotting was associated with active cancer disease, genitourinary tumor, lower citrate dose and lower INR. (C) 2018 Published by Elsevier Inc.-
dc.language.isoeng-
dc.publisherW B SAUNDERS CO-ELSEVIER INC-
dc.relation.ispartofJournal of Critical Care-
dc.rightsrestrictedAccess-
dc.subjectAcute kidney injury-
dc.subjectContinuous renal replacement therapy-
dc.subjectRegional citrate anticoagulation-
dc.subjectCancer patients-
dc.subjectIntensive care unit-
dc.subject.otherrenal replacement therapy-
dc.subject.otherrandomized controlled-trial-
dc.subject.otherlow-efficiency dialysis-
dc.subject.otherintensive-care units-
dc.subject.otherheparin anticoagulation-
dc.subject.othervenous thromboembolism-
dc.subject.othersystemic heparin-
dc.subject.otheroutcomes-
dc.subject.othersurvival-
dc.subject.otherefficacy-
dc.titleUse of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury-
dc.typearticle-
dc.rights.holderCopyright W B SAUNDERS CO-ELSEVIER INC-
dc.identifier.doi10.1016/j.jcrc.2018.04.006-
dc.identifier.pmid29859647
dc.subject.wosCritical Care Medicine-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage302-
hcfmusp.description.endpage309-
hcfmusp.description.volume47-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000444896900049-
hcfmusp.origem.id2-s2.0-85047639117-
hcfmusp.publisher.cityPHILADELPHIA-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAzoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5-
hcfmusp.relation.referenceBenoit DD, 2005, NEPHROL DIAL TRANSPL, V20, P552, DOI 10.1093/ndt/gfh637-
hcfmusp.relation.referenceChew HK, 2006, ARCH INTERN MED, V166, P458-
hcfmusp.relation.referenceClaure-Del Gramdo R, 2011, CLIN J AM SOC NEPHRO, V6, P467, DOI 10.2215/CJN.02500310-
hcfmusp.relation.referenceCrew KD, 2009, J CLIN ONCOL, V27, P2151, DOI 10.1200/JCO.2008.19.6162-
hcfmusp.relation.referenceDarmon M, 2006, CRIT CARE, V10, DOI 10.1186/cc4907-
hcfmusp.relation.referenceDarmon M, 2007, INTENS CARE MED, V33, P765, DOI 10.1007/s00134-007-0579-1-
hcfmusp.relation.referenceDranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252-
hcfmusp.relation.referenceDurao MS, 2008, CRIT CARE MED, V36, P3024, DOI 10.1097/CCM.0b013e31818b9100-
hcfmusp.relation.referenceFalanga A, 2015, THROMB RES, V135, pS8, DOI 10.1016/S0049-3848(15)50432-5-
hcfmusp.relation.referenceFalanga A, 2014, CURR OPIN HEMATOL, V21, P423, DOI 10.1097/MOH.0000000000000072-
hcfmusp.relation.referenceFiaccadori E, 2007, NEPHROL DIAL TRANSPL, V22, P529, DOI 10.1093/ndt/gfl627-
hcfmusp.relation.referenceFinkel KW, 2014, RENAL DISEASE IN CANCER PATIENTS, P1-
hcfmusp.relation.referenceGattas DJ, 2015, CRIT CARE MED, V43, P1622, DOI 10.1097/CCM.0000000000001004-
hcfmusp.relation.referenceHANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747-
hcfmusp.relation.referenceHetzel GR, 2011, NEPHROL DIAL TRANSPL, V26, P232, DOI 10.1093/ndt/gfq575-
hcfmusp.relation.referenceHosmer DW, 1997, STAT MED, V16, P965-
hcfmusp.relation.referenceKidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT S, V3, P1, DOI [DOI 10.1038/KISUP.2012.76, 10.1038/kisup.2012.76]-
hcfmusp.relation.referenceKlingele M, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1870-3-
hcfmusp.relation.referenceKoyner JL, 2014, AM J KIDNEY DIS, V64, P394, DOI 10.1053/j.ajkd.2014.03.018-
hcfmusp.relation.referenceKutsogiannis DJ, 2005, KIDNEY INT, V67, P2361, DOI 10.1111/j.1523-1755.2005.00342.x-
hcfmusp.relation.referenceLameire N, 2008, CURR OPIN CRIT CARE, V14, P635, DOI 10.1097/MCC.0b013e32830ef70b-
hcfmusp.relation.referenceLevi M, 2014, THROMB RES, V133, pS70, DOI 10.1016/S0049-3848(14)50012-6-
hcfmusp.relation.referenceLevy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B-
hcfmusp.relation.referenceLombardi R, 2014, NEPHROL DIAL TRANSPL, V29, P1369, DOI 10.1093/ndt/gfu078-
hcfmusp.relation.referenceMaccariello E, 2011, NEPHROL DIAL TRANSPL, V26, P537, DOI 10.1093/ndt/gfq441-
hcfmusp.relation.referenceMehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713-
hcfmusp.relation.referenceMEHTA RL, 1990, KIDNEY INT, V38, P976, DOI 10.1038/ki.1990.300-
hcfmusp.relation.referenceMonchi M, 2004, INTENS CARE MED, V30, P260, DOI 10.1007/s00134-003-2047-x-
hcfmusp.relation.referenceMorgera S, 2009, CRIT CARE MED, V37, P2018, DOI 10.1097/CCM.0b013e3181a00a92-
hcfmusp.relation.referenceOudemans-van Straaten HM, 2009, CRIT CARE MED, V37, P545, DOI 10.1097/CCM.0b013e3181953c5e-
hcfmusp.relation.referencePark MR, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.07.006-
hcfmusp.relation.referenceSalahudeen AK, 2009, CLIN J AM SOC NEPHRO, V4, P1338, DOI 10.2215/CJN.02130309-
hcfmusp.relation.referenceSandhu R, 2010, CANCER-AM CANCER SOC, V116, P2596, DOI 10.1002/cncr.25004-
hcfmusp.relation.referenceSchneider AG, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1880-1-
hcfmusp.relation.referenceSEYMOUR JF, 1993, BLOOD, V82, P1383-
hcfmusp.relation.referenceSilva V, 2016, PLOS ONE, V11-
hcfmusp.relation.referenceSoares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e-
hcfmusp.relation.referenceStevens LA, 2010, AM J KIDNEY DIS, V56, P486, DOI 10.1053/j.ajkd.2010.03.026-
hcfmusp.relation.referenceStevens PE, 2013, ANN INTERN MED, V158, P825, DOI 10.7326/0003-4819-158-11-201306040-00007-
hcfmusp.relation.referenceStucker F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0822-z-
hcfmusp.relation.referenceTaccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713-
hcfmusp.relation.referenceVincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156-
hcfmusp.relation.referenceZivin JR, 2001, AM J KIDNEY DIS, V37, P689-
dc.description.indexMEDLINE-
dc.identifier.eissn1557-8615-
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/08
LIM/08 - Laboratório de Anestesiologia

Artigos e Materiais de Revistas Científicas - LIM/12
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais

Artigos e Materiais de Revistas Científicas - LIM/29
LIM/29 - Laboratório de Nefrologia Celular, Genética e Molecular

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_SILVA_Use_of_regional_citrate_anticoagulation_for_continuous_venovenous_2018.PDF
  Restricted Access
publishedVersion (English)430.35 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.